The hepatocyte export carrier inhibition assay improves the separation of hepatotoxic from non-hepatotoxic compounds



Brecklinghaus, Tim, Albrecht, Wiebke, Kappenberg, Franziska, Duda, Julia, Vartak, Nachiket, Edlund, Karolina, Marchan, Rosemarie, Ghallab, Ahmed, Cadenas, Cristina, Günther, Georgia
et al (show 13 more authors) (2022) The hepatocyte export carrier inhibition assay improves the separation of hepatotoxic from non-hepatotoxic compounds. Chemico-Biological Interactions, 351. p. 109728.

Access the full-text of this item by clicking on the Open Access link.

Abstract

An in vitro/in silico method that determines the risk of human drug induced liver injury in relation to oral doses and blood concentrations of drugs was recently introduced. This method utilizes information on the maximal blood concentration (C<sub>max</sub>) for a specific dose of a test compound, which can be estimated using physiologically-based pharmacokinetic modelling, and a cytotoxicity test in cultured human hepatocytes. In the present study, we analyzed if the addition of an assay that measures the inhibition of bile acid export carriers, like BSEP and/or MRP2, to the existing method improves the differentiation of hepatotoxic and non-hepatotoxic compounds. Therefore, an export assay for 5-chloromethylfluorescein diacetate (CMFDA) was established. We tested 36 compounds in a concentration-dependent manner for which the risk of hepatotoxicity for specific oral doses and the capacity to inhibit hepatocyte export carriers are known. Compared to the CTB cytotoxicity test, substantially lower EC<sub>10</sub> values were obtained using the CMFDA assay for several known BSEP and/or MRP2 inhibitors. To quantify if the addition of the CMFDA assay to our test system improves the overall separation of hepatotoxic from non-hepatotoxic compounds, the toxicity separation index (TSI) was calculated. We obtained a better TSI using the lower alert concentration from either the CMFDA or the CTB test (TSI: 0.886) compared to considering the CTB test alone (TSI: 0.775). In conclusion, the data show that integration of the CMFDA assay with an in vitro test battery improves the differentiation of hepatotoxic and non-hepatotoxic compounds in a set of compounds that includes bile acid export carrier inhibitors.

Item Type: Article
Uncontrolled Keywords: Cells, Cultured, Mitochondria, Hepatocytes, Humans, Fluoresceins, Cytotoxins, Cell Culture Techniques, Toxicity Tests, Chemical and Drug Induced Liver Injury, ATP Binding Cassette Transporter, Subfamily B, Member 11, Multidrug Resistance-Associated Protein 2
Divisions: Faculty of Health and Life Sciences
Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology
Depositing User: Symplectic Admin
Date Deposited: 28 Jan 2022 09:36
Last Modified: 18 Jan 2023 21:14
DOI: 10.1016/j.cbi.2021.109728
Open Access URL: https://doi.org/10.1016/j.cbi.2021.109728
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3147755